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Targeted protein degradation tools are becoming a new therapeutic modality, allowing small
molecule ligands to be reformulated as heterobifunctional molecules (PROteolysis Targeting
Chimeras, PROTACs) that recruit ubiquitin ligases to targets of interest, leading to ubiqui-
tination and destruction of the targets. Several PROTACs against targets of clinical interest
have been described, but detailed descriptions of the cell biology modulated by PROTACs are
missing from the literature. Here we describe the functional characterization of a PROTAC
derived from AURKA inhibitor MLN8237 (alisertib). We demonstrate efficient and specific
destruction of both endogenous and overexpressed AURKA by Cereblon-directed PROTACs.
At the subcellular level, we find differential targeting of AURKA on the mitotic spindle
compared to centrosomes. The phenotypic consequences of PROTAC treatment are there-
fore distinct from those mediated by alisertib, and in mitotic cells differentially regulate
centrosome- and chromatin- based microtubule spindle assembly pathways. In interphase
cells PROTAC-mediated clearance of non-centrosomal AURKA modulates the cytoplasmic
role played by AURKA in mitochondrial dynamics, whilst the centrosomal pool is refractory to
PROTAC-mediated clearance. Our results point to differential sensitivity of subcellular pools
of substrate, governed by substrate conformation or localization-dependent accessibility to
PROTAC action, a phenomenon not previously described for this new class of degrader
compounds.
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The advent of targeted protein degradation tools that exploitthe endogenous protein degradation machinery to elim-inate disease proteins from the cell has started a revolution
in therapeutic strategy and drug design1. One novel way to target
proteins for degradation is through PROteolysis Targeting Chi-
meras (PROTACs), consisting of a chimeric molecule that binds
at one end to a protein target, and at the other to a ubiquitin
ligase (E3), most commonly the Cereblon (CRBN) substrate
recognition protein together with the CUL4A E3 ligase complex,
or to the von Hippel Lindau (VHL) protein in association with
the CUL2 complex2,3. This PROTAC-mediated ternary complex
formation between functional E3 and target protein facilitates
ubiquitin transfer, leading to ubiquitination of the target and its
proteolysis at the 26S proteasome.
This new paradigm of “event-driven” pharmacology (in con-
trast to the use of traditional “occupancy-based” drugs) holds
great hope for the development of catalytic drugs able to work at
lower doses, and with higher specificity than the ligands from
which they are derived. Moreover, the altered pharmacodynamics
of substrate destruction versus inhibition raises the possibility of
repurposing small molecule ligands (including those that have
failed clinical trials as inhibitors of their targets) into PROTACs.
However, although a number of publications document the suc-
cess of novel PROTACs in eliminating their cellular targets, there
has been little impact of this technology so far in the field of cell
biology. PROTACs have clear potential as tools for cell biology
that can perturb cellular protein functions on a timescale more
favorable than siRNA-mediated interference, and in a way that
does not depend on effective inhibition of an enzymatic function.
In this study, we investigate the properties of a PROTAC tool
based on a known small molecule inhibitor of the mitotic kinase
Aurora A (AURKA), MLN8237 (also known as alisertib)4–6.
AURKA is a well-studied regulator of mitosis, playing critical
roles in centrosome maturation, mitotic timing, microtubule
nucleation, and spindle assembly7,8. Distinct populations of
AURKA are either recruited to centrosomes by CEP192, or on
spindle microtubules (MTs) via the MT-associated protein TPX2.
These separate populations can be independently perturbed
through disruption of either interaction9–11. AURKA activity at
centrosomes contributes to mitotic entry. Activation of AURKA
is thought to occur either through auto-phosphorylation in the T-
loop (at T287/288), a process promoted by CEP192 oligomer-
ization at the centrosomes, or through interaction with a number
of known binding partners that act to stabilize the “DFG-In”
conformation to favor kinase activity independently of T-loop
phosphorylation12–14. The best-known of these interactors is
TPX2. At nuclear envelope breakdown (NEB), TPX2 is released
by importin-α, under the influence of the RanGTP gradient
around the mitotic chromosomes, to bind and activate AURKA.
In vitro tests show that binding by TPX2 and T-loop phos-
phorylation independently activate AURKA approximately 100-
fold15,16. These separable intracellular AURKA activities (defined
by pT288 at the centrosomes and TPX2 binding around chro-
matin) contribute to distinct pathways of MT nucleation that act
together to achieve mitotic spindle assembly. Critical targets of
AURKA in both pathways are NEDD1 and TACC3. Recruitment
and phosphorylation of NEDD1 allows recruitment of the γ-
TURC nucleating complex whilst phosphorylation of TACC3
promotes assembly of a pTACC3-ch-TOG-clathrin complex17
proposed to stabilize parallel MTs in the spindle.
AURKA undergoes targeted proteolysis in every cell cycle as a
substrate of the anaphase-promoting complex (APC/C) ubiquitin
ligase at mitotic exit18,19. However, AURKA is detectable in
interphase cells and has been attributed a number of non-mitotic
roles including ciliation control, cell cycle regulation of MYCN-
dependent transcription, DNA damage pathways, and
mitochondrial regulation20–23. Overall, there is a growing interest
in the roles played by AURKA outside of mitosis and their
contribution to its cancer-promoting activity. AURKA has long
been a postulated therapeutic target due to its well-documented
overexpression in cancer, although the role it plays in oncogenesis
is far from clear. Recent structural and conformational studies
have led to improved understanding of its mode of activation, and
the realization that multiple active forms may persist through
interphase that depend on different binding partners. Recent
work from our lab has shown that un-degraded AURKA retains
activity after mitosis24.
Therefore, a PROTAC tool able to eliminate AURKA protein
could be an important cell biology tool as well as a potential
therapeutic strategy. Here, we test characteristics of PROTAC
activity directed against AURKA and investigate the cell biology
that accompanies targeted protein degradation of this critical
cellular target.
Results
AURKA-Venus is sensitive to CRBN-directed PROTACs. We
set out to investigate the action of AURKA-directed targeted
protein degradation tools (PROTACs) against AURKA in single
cell time-lapse assays using cell lines that we have previously
described25: an AURKA-Venus knock-in line in RPE1 cells
(AURKA-VenusKI), where AURKA-Venus recapitulates expres-
sion of the endogenous protein (undetectable in interphase cells
and strongly upregulated for mitosis), and a line expressing
exogenous AURKA-Venus under tetracycline control (RPE1FRT/
TO-AURKA-Venus, AURKA-VenusTO) where higher levels of
expression occur throughout the cell cycle. We used AURKA-
VenusKI and AURKA-VenusTO cells arrested in mitosis by an
agonist of the Spindle Assembly Checkpoint (SAC), STLC, to test
the activity of PROTAC compounds (Fig. 1).
We synthesized eight PROTAC molecules consisting of the
well-characterized inhibitor of AURKA, MLN8237, linked to
either a known ligand of von Hippel-Lindau (VHL) E3 ligase or to
the thalidomide derivative, pomalidomide, to recruit Cereblon
(CRBN). As the linker is an integral part of the PROTAC molecule
and linker length can be a key determinant of PROTAC function,
we designed four molecules for each E3 with varying polyethylene
glycol (PEG) linker lengths (Table 1, Supplementary Fig. S1).
We found that CRBN-based PROTAC compounds were able
to elicit destruction of both AURKA-VenusKI and AURKA-
VenusTO in time-lapse movies of mitotic arrested cells (Fig. 1a±d).
Compound D reduced AURKA levels in a dose dependent
manner (Fig. 1b, c) with an EC50 in the 100 nM range (Fig. 1b).
At a dose of 1 µM, Compound D caused loss of AURKA-Venus
with t1/2 approximately 2 h (Fig. 1c). The activity of the PROTAC
against AURKA-VenusKI in time-lapse assays (Fig. 1d), or against
endogenous AURKA in extracts from mitotic arrested HeLa cells
(Fig. 1e, f), appeared to correlate with linker length, suggesting
that topological constraints limit the efficacy of PROTAC action.
The VHL-based PROTACs tested were inactive in all but one
dose (Fig. 1d). Taken together, the most efficient PROTAC tested
in these initial experiments was Compound D, which we named
AURKA-PROTAC-D (PROTAC-D). We tested the correlation
between linker length and efficacy of the PROTAC by creating a
new compound with an extra long linker, Compound DX
(Table 1). As predicted, Compound DX reduced AURKA levels
more efficiently than PROTAC-D (Fig. 1g). We tested the
specificity of PROTAC action of CRBN-directed compounds in
further experiments (Fig. 1h, i) demonstrating that neither
MLN8237 nor the CRBN ligand (pomalidomide) on its own
affected AURKA levels (Fig. 1h). In addition, the action of
Compound D was blocked by competition with excess
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pomalidomide (Fig. 1i), supporting that recruitment of CRBN E3
holo-complex was necessary for AURKA level reduction.
PROTAC-mediated degradation of AURKA-Venus is inde-
pendent of mitotic pathways of destruction. While analysing
these experiments, we noticed that AURKA-VenusKI cells
arrested in mitosis with STLC were more likely to exit mitosis
after treatment with PROTAC than after treatment with DMSO.
As we wanted to be able to separate PROTAC treatment effects
caused by target degradation from any residual inhibitory effects
caused by on-target engagement, we used Compound A (Cpd A)
as a negative control. Cpd A is a MLN8237-VHL molecule of
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identical linker length to PROTAC-D that did not cause degra-
dation of AURKA (Fig. 1d). It had a small and non-significant
effect in promoting mitotic slippage compared to PROTAC-D
(Fig. 2a). Since AURKA is itself a substrate of mitotic exit
degradation under control of the APC/CFZR1, failure of the SAC,
leading to activation of the APC/C, would be predicted to result
in degradation of AURKA independently of PROTAC-mediated
ubiquitination. Therefore, in the single cell mitotic degradation
assays shown in Fig. 1, we quantified only cells that remained
arrested in mitosis for the duration of the assay. However, we also
carried out experiments to test directly whether mitotic degra-
dation pathways were involved in PROTAC-D-driven dis-
appearance of AURKA-Venus using a combination of drugs
(APCin, proTAME), that inhibits the activity of the APC/C
ubiquitin ligase26. Degradation of AURKA-Venus in response to
PROTAC-D was not prevented by inhibition of APC/C (Fig. 2b,
c) and was therefore independent of mitotic exit.
The effect of PROTAC-D in promoting mitotic exit could
potentially be explained by a number of studies showing a role for
AURKA in the SAC27–29, but could also occur through “mitotic
slippage”, should there be any non-specific targeting of Cyclin B1
by PROTAC-D in the presence of an active SAC30. We tested this
possibility using a RPE1-cyclin B1-VenusKI line31. Degradation of
Cyclin B1-Venus and escape of cells from SAC-induced arrest
were both strongly promoted by PROTAC-D (Fig. 2d, e), and
weakly by Cpd A. However, in contrast to AURKA-VenusKI
degradation (Fig. 2b), Cyclin B1-VenusKI degradation measured
upon PROTAC-D treatment was sensitive to APC/C inhibition
(Fig. 2f). These results allowed us to conclude that Cyclin
B1-Venus degradation in the presence of PROTAC-D is the result
of a weakened SAC and that Cyclin B1 is not targeted directly by
PROTAC-D.
In further experiments to test that degradation of AURKA in
response to PROTAC-D was independent of the well-characterized
APC/C-dependent pathway, we used versions of AURKA known to
be resistant to APC/C-mediated degradation. AURKA possesses an
atypical APC/C degron motif, the so-called A-box, in its N-terminal
disordered region32. The A-box function appears to be negatively
regulated through phosphorylation on Ser51, since phospho-mimic
substitution (S51D) at this site blocks mitotic degradation of
AURKA33,34. We found, using single cell time-lapse degradation
assays, that an A-box deleted (Δ32-66) version of AURKA-Venus
stably expressed in an RPE-FRT/TO line was efficiently degraded in
response to PROTAC-D (Fig. 2g). We concluded that PROTAC-
mediated degradation of AURKA does not require the substrate
motif essential for its canonical degradation, either for ubiquitination,
or at any downstream step in substrate processing at the 26S
proteasome. We additionally tested the S51D version of AURKA-
Venus alongside the WT protein in time-lapse degradation assays,
after transient transfection into U2OS cells. We found not only that
both WT and “non-degradable” S51D were sensitive to PROTAC-D
in mitotic cells (Fig. 2h), but that they were also sensitive in
interphase cells (Fig. 2i), as further confirmation that PROTAC-
mediated processing of AURKA for destruction is independent of cell
cycle-dependent pathways. We note that the measured rate of
degradation is lower in interphase cells than mitotic cells, most likely
because degradation is masked by ongoing synthesis (observed as
accumulation of the protein in DMSO-treated control cells). We
concluded that degradation of AURKA measured in response to
PROTAC-D treatment is a direct consequence of PROTAC-D-
mediated targeting. Furthermore, since some experiments were
carried out using high-level transient expression of transfected
constructs (Fig. 2h, i), PROTAC-D appears potent enough to clear
target protein at significant levels of overexpression in the cell.
PROTAC-D action is highly selective for AURKA. Next, we
asked whether target destruction mediated by PROTAC-D was
specific for AURKA. Since the PROTAC target ligand MLN8237
has a degree of selectivity for AURKA over its cellular paralogue
AURKB, but is not completely specific (it inhibits AURKB
activity at doses of ≥50 nM4, and the reported selectivity ratio
AURKA-TPX2(1–43): AURKB-INCENP(783–918) is approximately
5-fold6), we might expect to find some degradation of AURKB in
response to a PROTAC carrying the MLN8237 warhead.
Fig. 1 AURKA destruction following treatment with CUL4-based PROTACs. a–d AURKA-VenusKI degradation in STLC-arrested RPE-1 cells, measured by
quantitative timelapse imaging. a Examples of fields of cells treated with a PROTAC (Compound D) or vehicle control (DMSO). Venus fluorescence was
measured in individual cells and plotted as an end-point assay (percentage of AURKA-VenusKI degradation after 3 h) (b) or as percentage of AURKA-
VenusKI remaining over time (to show the kinetics of degradation) (c). b Scatter plots showing response to different doses of PROTAC (Compound D) or
DMSO, with whiskers indicating mean ± SDs. c Time-course of AURKA-VenusKI degradation plotted as mean fluorescence ± SDs at each time point (n≥ 7
cells). d Comparison of percentage degradation of AURKA-VenusKI after treatment with potential PROTAC compounds directed to CUL4A (via CRBN) or
CUL2 (VHL) ubiquitin ligases (listed in Table 1). Scatter plots show pooled results from two separate experimental repeats with whiskers indicating mean
values and SDs. Results of Kruskal–Wallis multiple ANOVA, and the Dunn’s post-hoc multiple comparison test to DMSO are indicated. e, f Degradation of
endogenous AURKA in HeLa cells following 3 h treatment with PROTACs, with or without 42 µM proteasome inhibitor MG132, measured by quantitative
immunoblotting (e) to plot percentage protein remaining, ordered to show increasing linker size across the series (f). g U2OS and HeLa cells were treated
for 3 h with 250 nM Compound D (PROTAC-D) or a new compound with increased linker length (PROTAC-DX). Endogenous AURKA levels were
measured by immunoblot and plotted as percentage remaining compared to DMSO treatment after normalization to GAPDH loading control. The
experiment shown is one of two repeats that gave identical results. h Degradation of AURKA-VenusKI was measured in prometaphase cells treated with
1 μM PROTAC-D, MLN8237, or pomalidomide. Kruskal–Wallis multiple ANOVA, and the Dunn’s post-hoc multiple comparison test to DMSO, showed that
only PROTAC-D caused significant AURKA-Venus degradation. i Degradation of endogenous AURKA was quantified by immunoblot from mitotic-enriched
U2OS cells treated with 250 nM PROTAC D in the presence of 1–40-fold molar excess of pomalidomide. Data representative of two experiments (the
other in HeLa cells). Only cells that did not exit mitosis during filming (scored as onset of cortical contractility followed by respreading) were included in
the analyses shown in Fig. 1a–d, h).
Table 1 Summary of compounds tested.
Cpd Substrate ligand
(“warhead”)
E3 ligand target Linker length
(Mr)*
A MLN8237 (alisertib) VHL 288
B MLN8237 CRBN 272
C MLN8237 VHL 200
D MLN8237 CRBN 316
DX MLN8237 CRBN 404
E MLN8237 VHL 244
F MLN8237 CRBN 228
G MLN8237 VHL 156
H MLN8237 CRBN 184
*Mr relative molecular weight.
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Fig. 2 CUL4-mediated AURKA destruction is independent of known pathways of AURKA degradation. a RPE1-AURKA-VenusKI cells treated as in Fig. 1d
were scored for mitotic slippage (exit from mitosis in presence of STLC). Percentage of cells undergoing slippage after 3 h treatment with PROTAC-D or
Cpd A is shown relative to DMSO-treated cells. Mean values were generated from three identical experiments (where n≥ 30 cells), plotted with error bars
to indicate SDs and tested by ordinary one-way ANOVA with Dunnett’s post-hoc test for significance. b, c Degradation of AURKA-Venus in mitotic-
arrested RPE1-AURKA-VenusKI cells after treatment with PROTAC-D in the presence of APCin/proTAME. Degradation was measured in single cell assays,
with data shown as scatter plots (bars to indicate means ± SDs) tested with unpaired t-Test or Mann–Whitney U-test for significance (b) or visualized as a
time-course of drug treatment by immunoblot (c). d–f RPE1-Cyclin B1-VenusKI cells treated with PROTACs to investigate mitotic slippage. Increased
degradation of Cyclin B1–Venus following PROTAC-D treatment (d), correlates with increased rate of mitotic exit (e) (both results statistically tested by
ordinary one-way ANOVA with Dunnett’s post-hoc test for significance) and is blocked by co-treatment with APC/C inhibitors APCin (40 µM) and
proTAME (20 µM) (unpaired t-Test or Mann Whitney U-test for significance) (f). g–i “Non-degradable” AURKA-Venus is degraded efficiently in response
to PROTAC-D: AURKA-Venus-Δ32-66 (ΔA-box) expressed in RPE1 cells (tet-inducible RPE1-FRT/TO pool) is sensitive to PROTAC-D (unpaired t-test for
significance) (g). WT or Ser51D versions of AURKA-Venus transiently electroporated into U2OS cells are equally sensitive to PROTAC-D treatment in
either mitotic cells arrested by STLC (h) or interphase cells (i) (unpaired t-test or Mann–Whitney U-test for significance). Ongoing protein synthesis is
likely to mask the degradation rate of Venus-tagged protein in interphase cells.
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Furthermore, considering that within the mitotic cell AURKA
resides in multiprotein complexes governing its localization and
function, we hypothesized that the “ectopic” recruitment of ubi-
quitination machinery by PROTAC-D might lead to ubiquitina-
tion and destruction of AURKA binding partners. Therefore, we
examined if PROTAC-D caused a reduction in cellular levels of
AURKB, or of two well-known interacting partners of AURKA,
TPX2 and TACC3 (Fig. 3).
Surprisingly, we found that treatment with PROTAC-D caused
very little degradation of AURKB-Venus in an inducible U2OS
cell line (Fig. 3a), or of endogenous AURKB in HeLa cells
(Fig. 3b, c). We also found no degradation of endogenous TPX2
in mitotically-enriched HeLa cells after 3 h of treatment with
PROTAC-D (Fig. 3b, c). TPX2 and TACC3 levels were
unchanged in cells treated for up to 12 h, when endogenous
AURKA was no longer detectable (Fig. 3d). Therefore PROTAC-
D-mediated destruction is highly specific for AURKA. The
stability of AURKA binding partners in presence of PROTAC-D
suggests that the ubiquitination step is selective for the AURKA
moiety of mitotic complexes, or alternatively, that only unbound
AURKA is targetable by PROTAC-D.
Given the unexpected resistance of AURKB to AURKA
PROTAC action, we compared in vitro kinase inhibition activities
for AURKA and AURKB of PROTACs –D and –DX, Cpd A, and
their warhead MLN8237. We found that both of the PROTACs
had greater selectivity for AURKA over AURKB than MLN8237
in kinase inhibition assays (fold selectivity of PROTAC-D= 21.6,
PROTAC-DX= 23.7, MLN8237 ≥ 8.3) (Table 2), consistent with
the lack of AURKB degradation seen in Fig. 3a–c. Increased
selectivity for AURKA suggests that the increased size and/or
complexity of the PROTAC creates new steric parameters
influencing target discrimination, and is consistent with pub-
lished findings from others that the requirement for ternary
complex formation in PROTAC action can build a further layer
of specificity into drug action35,36. Comparing IC50 values for
inhibition of in vitro kinase activity of PROTAC-D and
PROTAC-DX versus MLN8237, we found that inhibition of
AURKA kinase activity by the PROTAC molecules is weaker than
that mediated by MLN8237 (5–10-fold). Interestingly PROTAC-
DX, which has stronger PROTAC activity in comparison to
PROTAC-D (Fig. 1g), does not have higher activity in this assay
(Table 2, Supplementary Fig. S2). This finding is in line with the
idea that the efficiency of PROTAC activity is not only impacted
by binding affinity to the target or E3 ligase, but also related to
efficiency of ternary complex formation between E3 and target
protein37.
Centrosome-localized AURKA is not sensitive to PROTAC-D.
Having validated PROTAC-D as an effective and specific tool
for depletion of cellular AURKA, we investigated how PROTAC-
Fig. 3 Specificity of AURKA targeting by PROTAC-D. a U2OS cells expressing tet-regulated AURKA-Venus and AURKB-Venus were arrested in mitosis
with STLC and treated with 250 nM PROTAC-D for 3 h. Scatter plots with mean values and SDs indicated show percentage degradation of protein in
individual cells pooled from three separate experiments, statistical test applied was Mann–Whitney U-test. b–d Endogenous levels of AURKA interactors
TPX2 and TACC3, or of AURKB, were examined by quantitative immunoblotting of extracts from cells arrested in mitosis with STLC and treated with
PROTAC-D or vehicle control (DMSO). b HeLa cells treated for 3 h, immunoblot representative of data from three identical experiments quantified and
presented in c, showing mean percentages of protein remaining after PROTAC-D treatment, relative to DMSO treatment, with error bars to indicate SDs.
d RPE1 AURKA-VenusKI cells treated for 12 h, immunoblot from one experiment.
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mediated AURKA destruction would compare to enzymatic inhi-
bition as a method for down-regulating AURKA functions in mitotic
cells. We fixed cell populations synchronized for passage through
mitosis and treated for 4 h with parallel doses of PROTAC-D or
MLN8237, or with DMSO as a negative control, and stained them by
immunofluorescence (IF) for the presence of AURKA, markers of
AURKA activity and tubulin, in order to assess the phenotypic
consequences of treatment with different compounds (Fig. 4). We
looked first at AURKA staining and found that cells treated with
PROTAC-D displayed a marked loss of the pool of AURKA asso-
ciated with the spindle (seen in DMSO-treated controls). However,
AURKA was preserved at the centrosomes (Fig. 4a). By contrast,
treatment with MLN8237 abrogated almost all AURKA localization
to centrosomes, consistent with the known role of AURKA activity
in centrosome maturation that includes recruitment of AURKA to
the pericentriolar material (PCM)38. This finding suggested that the
centrosome-associated pool of AURKA seen in PROTAC-D-treated
mitotic cells would be unexpectedly active (that is, neither degraded
nor inhibited by PROTAC treatment). We tested this idea by
measuring levels of pSer83-LATS2 as a well-known centrosomal
marker of AURKA activity, finding that this marker was entirely
resistant to PROTAC-D treatment (at doses sufficient to deplete
most of the cellular pool of AURKA), whilst responding in dose-
dependent fashion to MLN8237 (Fig. 4b, c).
Given the >5-fold difference in enzyme inhibition of PROTAC-
D and MLN8237 (Table 2) and the likelihood that the
intracellular dose of PROTAC-D is limited by its size and
solubility, we examined the phenotypic consequences of treat-
ment over a 10-fold range of doses of both compounds, scoring
mitotic figures according to the categories illustrated in
Supplementary Fig. S3. Dose-response to MLN8237 treatment
is characterized by progression from spindle orientation defects at
low doses to spindle assembly defects (multipolar spindles,
“small” spindles) at intermediate doses, to lack of MT nucleation
at a dose of 250 nM (Fig. 4d and as previously described4). We
were surprised to find that PROTAC-D-treated cells showed none
of these defects (Fig. 4d, e). Even at the highest dose tested (250
nM), we did not see the orientation defects characteristic of low
dose inhibition of AURKA activity4,39. Instead, we observed that
the mitotic spindles were shorter in length after PROTAC
treatment. Distribution of the centrosomal pLATS2 staining
shown in Fig. 4b confirms that the pole-to-pole distance of
correctly oriented bipolar spindles is reduced (Fig. 4f).
PROTAC-D and MLN8237 mediate distinct effects in mitotic
cells. Our finding of “short spindles” was reminiscent of the
previously reported finding that specific perturbation of AURKA
binding to TPX2 controls spindle length independently of any
effect on assembly11, which can occur under the influence of the
centrosomal AURKA pool. Therefore, we hypothesized that
PROTAC-D had selectively depleted the TPX2-associated pool of
AURKA to eliminate the chromosome-centered MT nucleation
pathway whilst leaving the centrosomal pathway untouched. We
decided to test this idea using a modified cell synchronization
assay that would better allow us to compare the roles of kinase
inhibition and target degradation in mitotic cells independent
of their different effects on AURKA-dependent centrosome
maturation. We pre-synchronized cells at metaphase by release of
cells arrested for 24 h in Thymidine into APCin/proTAME for 6 h.
We then treated metaphase-arrested cells with different doses of
MLN8237, PROTAC-D and Cpd A for 3 h before fixing them for
IF analysis. We first examined the pT288 epitope as a direct
readout for inhibition of AURKA, finding as expected that
PROTAC-D and Cpd A show weaker inhibition of AURKA
activity than MLN8237. Importantly, the extent of inhibition by
PROTAC-D and Cpd A is similar, confirming that both are able to
access the centrosomal pool of AURKA (Fig. 5a, b) and enabling
us to reason that comparing the effects of these compounds would
reveal phenotypes arising from degradation of AURKA, distinct
from those arising purely out of kinase inhibition.
Next, we stained cells for AURKA and its interactors CEP192
and TPX2 (Fig. 5c–h). Similar levels of CEP192 at centrosomes
after the different treatments confirmed that centrosome
maturation had occurred in a large fraction of the cellular pool
of metaphase cells (Fig. 5c). Quantification of AURKA levels in
these cells showed the total cellular pool of AURKA reduced
more than three-fold after PROTAC-D treatment (Fig. 5d).
Measured AURKA levels were also somewhat lower (by about
30%) after treatment with Cpd A or with low (25 nM) or high
(250 nM) doses of MLN8237. Since we have found that these
treatments do not affect endogenous AURKA levels, nor
AURKA-Venus levels in intact cells, we assumed that the reduced
AURKA levels seen in IF reflected loss of AURKA in the fixation
step, that could be a consequence of reduced interaction with the
mitotic spindle. Indeed, MLN8237 and TPX2 may compete with
each other for AURKA binding40 (see “Discussion” section). We
measured pole-pole distances in this experiment and found them
reduced by PROTAC-D treatment. AURKA inhibition with 25
nM MLN8237 also gave rise to short spindles, whereas Cpd A had
no effect on spindle length (Fig. 5e). We concluded that Cpd A
and PROTAC-D both bind too weakly to AURKA to significantly
inhibit its activity, and that the short spindle phenotype seen after
PROTAC-D treatment depends on destruction of AURKA by
PROTAC-D. Consistent with this conclusion, we observed that
PROTAC-D alone of the three treatments removed both
cytoplasmic and spindle pools of AURKA (Fig. 5f). Kinase
inhibition mediated by 25 nM MLN8237 or 250 nM Cpd A
caused some loss of signal from the spindle, but also increased
cytoplasmic levels of AURKA (Fig. 5f, g). Comparison of AURKA
pixel intensities in fixed areas on the centrosome or neighboring
spindle confirmed that depletion of the spindle signal was greater
than at the centrosome (Fig. 5h). We concluded from our data
that PROTAC-D preferentially depletes the pool of AURKA that
associates with TPX2 to govern mitotic spindle length. Moreover,
because kinase inhibition assays indicate that Cpd A and
PROTAC-D bind AURKA with equivalent affinity (Fig. 5b and
Table 2), we concluded that the short spindle phenotype seen
after PROTAC-D—but not Cpd A—treatment (Fig. 5e) depends
on destruction of AURKA protein.
Selective depletion of distinct target pools by PROTAC-D.
We investigated further why PROTAC-D treatment led to
selective depletion of the spindle-associated pool of AURKA,
hypothesizing that this could be a consequence of conformation-
dependent targeting by the PROTAC, with the preferred target







PROTAC-D 3.58 77.2 21.6
PROTAC-DX 4.78 113 23.7
CpdA 6.17 95.4 15.5
Enzyme inhibition (IC50) of different compounds in in vitro kinase assays. IC50s are shown as
geometric means of three repeats (MLN8237, PROTAC-D, -DX) or two (Cpd A). Fold-
selectivity is expressed as the relative affinity for AURKA over AURKB.
aMeasured IC50 for AURKA is at the lower limit of dose range and below the theoretical tight
binding limit of the assay. Therefore true IC50 may be somewhat lower (and fold-selectivity
higher).
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being either the TPX2-bound pool or a free pool of AURKA
(provided this turns over faster with the TPX2-bound pool than
the centrosomal pool). We tested this idea by using conforma-
tional mutants of AURKA-Venus. AURKA-S155R is a version of
AURKA showing reduced interaction with TPX2 (and therefore
weak localization to the mitotic spindle), whilst its centrosomal
localization is maintained41. The non-catalytic N-terminal IDR
of AURKA is known to mediate interaction with a number of
binding partners42–44, so N-terminally truncated versions of
AURKA, 68–403 (Δ67) and 128–403 (Δ127), are predicted to
show reduced interactions with binding partners, including a
potential auto-inhibitory interaction with the kinase domain23,45.
Fig. 4 AURKA remains active at centrosomes upon PROTAC treatment. a–c Immunofluorescence analyses of U2OS cells synchronized through mitosis
and treated for 3 h with MLN8237, PROTAC-D, or DMSO vehicle control. AURKA staining is retained at the centrosomes after PROTAC-D treatment
(a) whilst a marker for active AURKA at centrosomes, p(Ser83)LATS2, persists after PROTAC-D treatment but not MLN8237 treatment (b, c).
c Measurement of centrosomal pLATS2 staining from immunofluorescence images after cytoplasmic background subtraction (Kruskal–Wallis multiple
ANOVA, and Dunn’s post-hoc multiple comparison test to DMSO for significance). d, e Mitotic phenotypes scored from TPX2/DAPI staining of fixed cells
(categories illustrated in Supplementary Fig. S3). d Dose-dependence of phenotypes using pooled data from three coverslips for each condition from a
single experiment. e Mitotic categories scored at a single dose (100 nM), using data from two coverslips each from three independent repeats of the
experiment, mean values ± SDs for each experiment are plotted. f Line-scans through fixed mitotic cells stained with pLATS2 (as shown in b), to show both
poles of the spindle (visible as maxima of staining intensity), reveal reduced pole–pole distance after PROTAC-D treatment. Traces show mean values from
n≥ 22 individual mitotic spindles, with fainter traces above and below representing SDs.
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We found that in RO3306-arrested interphase cells, over-
expressed S155R and wild-type versions of AURKA-Venus
showed a similar pattern of targeting by PROTAC-D. However
in cells arrested in prometaphase with STLC, where TPX2 is a
major binding partner of AURKA, S155R was more rapidly
degraded than the wild-type, consistent with the idea that
PROTAC-D preferentially depletes free AURKA in mitotic cells
(Fig. 6a). The N-terminally truncated version of AURKA Δ127
was insensitive to PROTAC-D, and in the absence of PROTAC
treatment accumulated strongly (Supplementary Fig. S4) and we
concluded that it probably lacks substrate lysines and/or IDR
required for ubiquitination or processing at the 26S proteasome.
The Δ67 version of AURKA-Venus was, however, more sensitive
to PROTAC-D than the full-length protein under all conditions
tested (Fig. 6b, and Supplementary Fig. S4). This finding is
consistent with the idea that interactions mediated through the
N-terminal IDR impede PROTAC-D-mediated degradation of
the target.
In order to confirm that subcellular pools of wild-type AURKA
also showed differential sensitivity to PROTAC-D, we experi-
mented instead on RPE1-AURKA-VenusKI cells treated with
siRNA against CEP192 (CEP192i) to displace AURKA from the
centrosomes10. Displacement of AURKA-Venus was readily
observed in cells arrested in G2 phase with RO3306, when
AURKA-VenusKI expression is high (Fig. 6d, quantified in
Supplementary Fig. S5). We tested AURKA-Venus degradation in
response to PROTACs under these conditions and measured
slightly increased degradation of AURKA-Venus in single cells or
by immunoblot (Supplementary Fig. S5). We then tested the
effect of CEP192i on mitotic cells, when a much larger pool of
AURKA is normally recruited to centrosomes. In STLC-arrested
cells we found that AURKA-VenusKI delocalized from centro-
somes after CEP192i (Fig. 6e, f) was more readily degraded in
response to PROTAC-D (Fig. 6g). We concluded that the
centrosome localized pool of AURKA-Venus shows reduced
sensitivity to PROTAC-D.
Inhibition of cytoplasmic AURKA activity by PROTAC-D.
Recent studies of AURKA have highlighted that interphase
functions may contribute to its tumorigenic activity. One inter-
phase function is regulation of the mitochondrial network and
our recent work has shown that excess AURKA present in
interphase FZR1KO cells causes fragmentation of the mitochon-
drial network24. This activity of AURKA, promoted through
stabilization of the protein, represents an interesting context for
testing PROTAC strategies, so we tested the action of PROTAC-
DX on mitochondrial fragmentation in FZR1KO cells. We treated
FZR1KO cells with PROTAC-DX and Cpd A and found that
PROTAC-DX, but not Cpd A, restores mitochondrial morphol-
ogy (Fig. 7a, b). Therefore PROTAC-DX is able to prevent
interphase activity of AURKA in a manner that depends on
destruction of the protein. We conclude that PROTAC-mediated
clearance is an efficient strategy for downregulating excess
AURKA activity in interphase cells.
Discussion
We have described a small molecule that acts as a specific
degrader of AURKA to clear endogenous, exogenous GFP-tagged,
or overexpressed protein from the cell. Amongst the molecules we
tested, successful degraders were CRBN-specific. Although, we
have not formally excluded the possibilities that VHL is insuffi-
ciently active in U2OS cells to generate degradation-competent
ubiquitin conjugates in response to Cpd A, or that the four linker
constructs we tested all occluded ternary complex formation
between AURKA and VHL, our observation that the same four
linker constructs were all able to support PROTAC activity
directed to CRBN are in line with the published finding that
protein–protein interaction surfaces of CRBN are more favorable
to stable ternary complex formation than the equivalent surfaces
of VHL37. As widely reported in the literature, PROTACs have
poor solubility and cell permeability. Therefore we also con-
sidered the possibility that our VHL-directed compounds are less
cell permeable than their CRBN-directed matching compounds,
by testing our VHL-directed “control” compound, Cpd A, for its
ability to inhibit AURKA activity both in cells as well as in vitro.
We found that PROTAC-D and Cpd A showed similar activity in
both assays (Fig. 5a and Table 2).
Compounds showing PROTAC activity against AURKA were
several-fold less potent than their MLN8237 warhead in inhi-
biting AURKA activity in vitro, consistent with reduced affinity
for their target. Indeed, we found that the partial inhibition of
AURKA activity in response to PROTAC-D treatment (pT288-
AURKA staining, Fig. 5) was insufficient to reduce AURKA
function at the centrosomes (pS83-LATS2 staining, Fig. 4), and
that non-centrosomal AURKA was insensitive to Cpd A inhibi-
tion (since mitotic spindle assembly was unaffected). Therefore
we concluded that binding of PROTAC-D is weak enough, and/
or the molecule present at sufficiently low intracellular levels, to
achieve targeted degradation of AURKA in absence of functional
consequences to the inhibition of AURKA kinase activity, and
without exhibiting the hook effect characteristic of hetero-
bifunctional ligands46. The question of the intracellular effective
dosage of PROTACs remains an elusive parameter.
Fig. 5 PROTAC specifically depletes AURKA on the mitotic spindle. U2OS cells were released from single thymidine block into APCin and ProTAME to
arrest at metaphase and pre-treated for 3 h with DMSO, PROTAC-D, Cpd A, or MLN8237 before fixation. Cells were then stained for AURKA, pT288-
AURKA and DAPI (a, b), AURKA, CEP192, and DAPI (c–e) or AURKA, TPX2, and DAPI (f–h). All data shown are representative of two identical
experiments. a Examples of cells imaged under different drug treatments and used for measurement of pT288-AURKA intensity at spindle poles. b Data
are shown as scatter plots with means and SDs indicated and were tested for statistical significance by ordinary one-way ANOVA with Dunnett’s post-hoc
test for significance to DMSO. c Examples of cells imaged under different drug treatments and used for measurement of total AURKA intensity after
background subtraction (d) or measurement of spindle pole separation as distance from one CEP192-marked centrosome to the other (e), shown as
scatter plots with means ± SDs indicated and tested by Kruskal–Wallis multiple ANOVA, and the Dunn’s post-hoc multiple comparison test to DMSO.
f Examples of cells imaged under different drug treatments and used to compare AURKA levels on the spindle and at the spindle poles. Insets indicated
with white boxes in AURKA channel are enlarged 4× in righthand panels and have contrast increased to reveal cytoplasmic levels of AURKA (arrowheads).
g, h Integrated AURKA intensities were measured within circles of fixed diameter centered on the centrosomes, spindle or cytoplasm to show the effect of
PROTAC-D treatment on different pools of AURKA and reveal that loss of AURKA from spindle and centrosomes in control drug treatments is reflected in
increased cytoplasmic levels (g) and that PROTAC-D treatment causes greater loss of AURKA from the spindle than from the centrosomes (h). Scatter
plots with means ± SDs indicated show measurements from individual cells from a single experiment. For plot g, values were normalized to mean DMSO
levels and tested by ordinary one-way ANOVA with Dunnett’s post-hoc test for significance to DMSO. For plot h, raw values were plotted using separate Y
axes for centrosome and spindle values (integrated over circles of 5 and 35 pixel diameters, respectively).
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We found that the activity of CRBN-directed molecules cor-
related with linker length but was independent of the affinity of
the compound for its AURKA target. Therefore, it is likely that
our longer linkers promote the assembly of productive ternary
complexes by bringing together AURKA and CRBN in an
orientation that allows the E3 complex to ubiquitinate AURKA at
appropriate lysine residues. The physical properties of the linker
are critical parameters in PROTAC activity, and further optimi-
zation of PROTAC-DX could include different linker patterns to
alter linker flexibility, as well as lengths.
We observed that clearance of wild-type AURKA from the cell
is less efficient than that mediated by its cognate E3, APC/C-
FZR1 (t1/2 ~100 min vs. t1/2 ~45 min18). We speculate that even
with further optimization, it seems unlikely that any PROTAC
would eliminate AURKA faster than its cognate pathway, since
the rate-limiting step for degradation of many ubiquitinated
substrates is not recruitment to the 26S proteasome, but deter-
minants of processing that are partly substrate-specific (such as
unfolding of substrate at the proteasome) and partly determined
by the configuration of ubiquitin chains47. Indeed, a recent study
Fig. 6 Differential targeting of AURKA pools. a–c Differential degradation of AURKA-Venus variants in response to PROTAC-D. U2OS cells were
transiently transfected with different versions of AURKA-Venus and treated for 16 h with RO-3306 to arrest them in G2 phase, or with STLC to arrest them
in mitosis. Cells were then treated with 250 nM PROTAC-D or DMSO as vehicle control and subjected to fluorescence timelapse microscopy over 3 h.
Venus levels in whole cells were measured at the start and end of each experiment to calculate percentage protein remaining for each cell. Scatter plots
show data from individual cells to compare wild-type and S155R versions (a) or wild-type, S155R and Δ67 versions under conditions of mitotic (b)
and interphase (c) arrest. Bars and whiskers represent mean values and SDs and are pooled from three repeats of the same experiment (unpaired t-test,
n≥ 10). d–g RPE1-AURKA-VenusKI cells were transfected for 48 h with siRNA against CEP192 (CEP192i) or control siRNA (GL2i) then either arrested in G2
phase with RO3306 (d) or arrested in mitosis with STLC (e–g) for 16 h before treatment with PROTAC-DX for 3 h. d Panels from start and end of
experiment show AURKA-Venus preserved at centrosomes in control cells even following PROTAC treatment, but absent from centrosomes in CEP192i
(See Supplementary Fig. S5 for quantification of this experiment). e Panels from start of experiment in STLC-arrested cells, showing reduced localization of
AURKA to the single spindle pole in each cell following CEP192i, as quantified in f: Mean pixel intensities of AURKA-Venus were measured within a region
of interest of fixed diameter around poles and in the cytoplasm, and are expressed as the ratio of spindle pole:cytoplasm after normalization of each dataset
with the mean value of the control sample. Data from individual cells in three independent repeats of the experiment were pooled, with the mean value of
each repeat plotted in red and tested for statistical significance using Mann–Whitney U-test. g In mitotic-arrested cells AURKA-VenusKI showed strongly
enhanced degradation after CEP192 knockdown in live cell degradation assays: Plots show percentage degradation in individual cells after 3 h treatment
and contain pooled data from two independent experiments with mean values from each experiment plotted in red (Mann Whitney U-test). A third
independent experiment was carried out, showing the same result but with response to PROTAC reduced in all conditions, with the pooled data shown in
Supplementary Fig. S6.
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found that the presence of unstructured regions determines the
PROTAC mediated degradation of VHL-directed substrates48.
However, we found that PROTAC-D could clear versions of
AURKA resistant to APC/C-mediated degradation (through
mutation or removal of the essential N-terminal degron) as effi-
ciently or better than the wild-type AURKA. We conclude from
this that the position and topology of ubiquitin chains assembled
on AURKA by CUL4A-CRBN and APC/C-FZR1 are likely to be
very different, and that PROTACs are promising tools for tar-
geting mutant versions of cellular proteins that have acquired
resistance to canonical degradation pathways.
We also observed that different cellular pools of AURKA
substrate were differentially targeted by PROTAC treatment,
since in mitotic cells the spindle-associated fraction of AURKA
was eliminated whilst the centrosome fraction was preserved
(Fig. 8). Since the centrosomal pool of AURKA retained its
activity, spindle assembly was buffered against the loss of the
chromatin-associated TPX2-activated AURKA pool and the
observed phenotype of PROTAC-D treatment in mitotic cells is
therefore shortened spindles, consistent with a previous study of
cells engineered to express a non-AURKA-binding version of
TPX211. Similarly, in interphase cells we observed that PROTAC-
D treatment efficiently cleared the non-centrosomal pool of
AURKA, but that centrosomal AURKA was preserved. Deloca-
lization of the centrosomal pool through siRNA-mediated
depletion of CEP192 promoted clearance of the total cellular
pool of AURKA-Venus by PROTAC-D. Since centrosomal
AURKA is efficiently inhibited by MLN8237, we would expect it
to be accessible to bind MLN8237-derived PROTAC molecules.
One explanation for its inaccessibility to PROTAC-D action
Fig. 7 PROTAC-D treatment restores the mitochondrial network in FZR1KO cells. U2OS FZR1KO cells, in which mitochondria are highly fragmented due to
the presence of excess AURKA24, were treated for 3 h with DMSO or with MLN8237, Cpd A or PROTAC-D at the doses indicated. Cells were then stained
with MitoTracker RedTM, imaged and analysed for mitochondrial fragment lengths as described in materials and methods. a Representative images of cells
analysed. Scalebar, 10 μm. b Scatter plots showing mean mitochondrial lengths, mean and SDs under different drug treatments. Each datapoint represents
the mean value from 30 mitochondria per cell, n≥ 12 cells, with results tested for significance using Mann–Whitney U-test. The data are from a single
experiment that is representative of two identical repeats of the same experiment.
Fig. 8 Targeting of non-centrosomal AURKA functions by PROTAC-D. Schematic to illustrate the distinct actions of MLN8237 and PROTAC-D on
AURKA pools in mitotic cells. Both centrosomal and spindle pools of AURKA are inhibitable by MLN8237, whereas PROTAC-D clears the spindle pool of
AURKA whilst leaving active AURKA at the centrosome. Figure made in ©BioRender (biorender.com).
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could be that centrosomal localization, or the interaction with
CEP192, block recruitment of CRBN or another component of
the E3 complex required for ubiquitination of its target. Alter-
natively, there may be deubiquitinase enzymes active at the
centrosomes that act to stabilize ubiquitinated AURKA.
Our results point to differential accessibility of subcellular pools of
substrate, governed by substrate conformation, binding partners, or
localization in compartments more or less accessible to PROTAC
action, a phenomenon that has not previously been described for
PROTAC agents acting via CRBN. Our finding of localized response
to PROTAC-D is in contrast with treatment by the AURKA inhi-
bitor alisertib, which promotes a clear dose-dependent depletion of
pLATS2, a marker of AURKA activity at the centrosomes.
Given the complex conformational and spatial regulation of
AURKA14,16 we tested for conformation-specific targeting of the
kinase using different versions of AURKA-Venus. The con-
formational dynamics of AURKA are strongly constrained
through interaction with TPX240,49,50, which favors the so-called
“DFG-In” active confirmation. A recent study from the Levinson
group suggests that different functional pools of the kinase pos-
sess distinct conformational properties that modulate interactions
with inhibitors, with alisertib/MLN8237 shown to be a “Type 1”
inhibitor that promotes the inactive DFG-Out state, and
TPX2 shown to oppose DFG-Out inducers, exhibiting negative
cooperativity on binding with MLN8237. In the DFG-Out state,
the active site is more open (i.e., more accessible to MLN8237 or
PROTAC-D) and in this model, a version of AURKA impaired in
TPX2 binding (S155R) should be more strongly degraded in
response to PROTAC-D where TPX2 is present. Indeed, we
found some difference in mitotic, but not interphase cells, con-
sistent with a competition model whereby AURKA bound by
TPX2 is less accessible to PROTAC-D binding. However, it is also
likely that AURKA in complex with binding partners is less
accessible for ternary complex formation with CRBN and other
components required for efficient ubiquitination in response to
PROTAC-D. We tested this idea with truncation of the non-
catalytic domain of AURKA to reduce interaction with some
binding partners, whilst not affecting the ability of PROTAC-D to
access the catalytic domain. Δ67 was degraded more efficiently
than the full-length protein under all conditions tested, consistent
with the idea that binding partners influence the ability of
PROTAC-D to bring about degradation of its target.
AURKA is of strong interest as a therapeutic target for various
cancers, but despite extensive testing in clinical trials, alisertib has
yet to reach the clinic. Our study is the first to describe a degrader
compound that shows specificity for different subcellular pools of
AURKA, raising the possibility of developing PROTACs to fine-
tune the activity of AURKA (and other targets that have shown
disappointing clinical results) to produce cellular phenotypes that
are potentially more desirable in pharmacological or therapeutic
contexts. For example, alisertib-derived PROTACs could be used
to target cytoplasmic functions of AURKA without inducing
mitotic errors that are the consequence of inhibiting AURKA
function at the centrosome.
Methods
Cell culture and synchronization. U2OS and HeLa cells were cultured in DMEM
(Thermo Fisher Scientific) and hTERT-RPE-1 cells in DMEM:F12 mix, supple-
mented with 10% FBS, 200 µM Glutamax-1, 100 U/ml penicillin, 100 µg/ml
streptomycin, and 250 ng/ml fungizone. All cells were grown in humidified
atmosphere at 37 °C with 5% CO2. RPE-1 AURKAKI cells, RPE-1 AURKATO cells,
Tet-Off cell lines U2OS-AURKA-Venus and U2OS-AURKB-Venus, have all been
previously described25,51.
For assaying live cell degradation of AURKA-VenusKI and AURKA-VenusTO in
mitotic arrested cells, 1.5 × 104 RPE1 AURKA-VenusKI cells were seeded per well
in 8-well slides (Ibidi GmbH) and treated for 16 h with 10 µM S-trityl L-cysteine
(STLC) (Tocris Bioscience) prior to PROTAC treatment.
For assaying live cell degradation of AURKA-VenusTO in G2 arrested cells,
1.5 × 104 RPE1 AURKATO cells were seeded per well in 8-well slides (Ibidi GmbH)
and treated for 16 h with 10 µM RO3306 (Tocris Bioscience) prior to PROTAC
treatment.
For assaying degradation by immunoblot of cell extracts, 2 × 105 AURKA-
VenusKI cells were seeded in 6-well plates prior to 16 h STLC treatment and
addition of test compounds.
Cells for immunofluorescence were seeded on glass coverslips and enriched for
the population of mitotic cells by release from a single 24 h block with 2.5 mM
Thymidine. Cells were fixed 10 h after release, to include the time of treatment with
test compounds.
For assaying mitochondrial fragmentation, U2OS FZR1KO cells24 seeded on 8-
well Ibidi slides were incubated for 15 min at 37 °C in MitoTracker Red® CMXRos
(Thermo Fisher Scientific) as per manufacturer’s instructions.
Drug treatments. AURKA PROTACs and pomalidomide were synthesized in-
house and used at ≤1 μM. Detailed chemical synthesis of Compounds A–H is
described in Supplementary Methods. Aurora A kinase inhibitor MLN8237
(Stratech, Ely, UK) was used at ≤1 μM, MG132 (Alfa Aesar) at 42 µM, RO3306
(Tocris Bioscience) at 10 µM, APCin (Bio Techne) at 20 µM and ProTame (R&D
Systems) at 40 µM.
Cell transfection. Cells were transfected with 1 µg of plasmids using electro-
poration with Neon Transfection System (Thermo Fisher Scientific) using the
following parameters: pulse voltage 150 V, pulse width 10 ms, and two pulses total
on the transfection device according to the manufacturer’s protocol. AURKA and
AURKB plasmids used were expressed with C-terminal Venus tags in pVenus-N1
vector. Δ32–66, S51D, S155R Δ67, and Δ127 versions of AURKA were generated
by PCR mutagenesis, with cloning maps available on request.
CEP192 knockdown was achieved by transfecting the oligo duplex: 5′-
GGAAGACAUUUUCAUCUCUtt-3′ and 5′-AGAGAUGAAAAUGUCUUCCtt-3′
(Sigma).
Immunoblotting. Cell extracts were prepared in NuPage (Invitrogen) SDS sample
buffer with 100 µM DTT, Extracts were syringed and boiled prior to electrophoresis
on NuPage precast 4–12% Bis–Tris SDS-PAGE gels (90 min, 150 V, 80W). Pro-
teins were transferred on to Immobilon-FL PVDF (Sigma) membrane using a wet
transfer XCell IITM Blot Module system (120 min, 30 V, 80W). Blocking and
incubations were performed in phosphate-buffered saline (PBS), 0.1% Tween-20,
5% low-fat milk (TBST and 3% BSA for phosphoantibodies) either overnight at
4 °C or for 1 h at room temperature. Signals were quantified by enhanced che-
miluminescence detection, or using fluorophore-conjugated secondary antibodies,
scanned on an Odyssey® Imaging System (LI-COR Biosciences). The uncropped
raw tif files for each blot are assembled in Supplementary Fig. S7.
Primary antibodies for immunoblot were as follows: AURKA mouse mAb
(1:1000; Clone 4/IAK1, BD Transduction Laboratories), phospho-Aurora A
(Thr288)/Aurora B (Thr232)/Aurora C (1:1000; clone D13A11 XP® Rabbit mAb,
Cell Signaling), rabbit polyclonal TPX2 antibody (1:1000; Novus Biological),
AURKB rabbit polyclonal antibody (1:1000; Abcam ab2254), mouse mAb Cyclin
B1 (1:1000; BD 554177), rabbit polyclonal beta-tubulin (1:2000; Abcam ab6046),
GAPDH rabbit mAb (1:400; Cell Signaling Technology #2118), TACC3 rabbit
polyclonal antibody (1:1000; gift from F. Gergely), and CEP192 affinity-purified
rabbit polyclonal antibody (1:1000; Gift from L. Pelletier52).
Secondary antibodies used were Polyclonal Goat Anti-Rabbit or Polyclonal
Rabbit Anti-Mouse (1:1000) HRP-conjugated (Dako Agilent), or IRDye® 680RD
(1:20,000)- or 800CW (1:10,000)-conjugated for quantitative fluorescence
measurements on an Odyssey® Fc Dual-Mode Imaging System (LICOR
Biosciences). IRDye® conjugated antibodies were prepared in PBS, 0.1% Tween-20,
5% FBS, 0.01% SDS.
Immunofluorescence. Cells were seeded at 2 × 104 onto glass coverslips and then
fixed with cold 100% methanol (−20 °C), permeabilized and blocked with 3%
bovine serum albumin (BSA) and 0.1% Triton X-100 in PBS (blocking buffer) for
15 min at room temperature. Cells were washed three times in PBS with 0.1%
Triton X-100 for 5 min each prior to 1 h incubation with primary antibodies
diluted in blocking buffer at room temperature in a humidity chamber. Slides were
then washed three times again in PBS with 0.1% Triton X-100 for 5 min each
before incubation with secondary antibodies diluted in blocking buffer for 45 min
at room temperature in a humidity chamber. DNA was stained with Hoechst-
33342 (1 µg/ml) and coverslips were mounted with Prolong Gold antifade reagent.
Primary antibodies used for immunofluorescence were as follows: AURKA
mouse mAb. (1:1000; Clone 4/IAK1, BD Transduction Laboratories), AURKA
rabbit polyclonal (1:1000; Abcam ab1287), PLATS2 mouse mAb (1:1000; Clone.
ST-3B11, Caltag Medsystems), TACC3 rabbit polyclonal antibody (1:1000; gift
from F. Gergely), TPX2 rabbit polyclonal (1:1000; Novus Biological).
CEP192 affinity-purified rabbit polyclonal antibody (1:1000; Gift from L.
Pelletier), beta-tubulin rabbit polyclonal (1:1000; Abcam ab6046), beta -tubulin
mouse mAb (1:300; Sigma T4026).
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Secondary antibodies used were: Alexa Fluor 488 anti-mouse and Alexa Fluor
568 anti-rabbit (Thermo Fisher Scientific).
Microscopy. All images were acquired on automated epifluorescence imaging
platforms based on Olympus IX81 or IX83 inverted microscopes (Olympus Life
Science, Southend-on-Sea, UK) with LED illumination source and motorized stage.
Time-lapse was carried out using cells seeded on Ibidi 8-well slides, and imaged at
37 °C in L-15 medium/10% FBS using a 40× NA1.3 OIL objective. Epifluorescent
stacks of fixed cells after processing by IF were acquired using 60× NA 1.0 OIL
objective with 200 nm step. Image acquisition was controlled by Micro-Manager53
and images exported as tiff files.
Image analysis and quantifications. Images were analysed using FIJI54, mea-
suring net green intensity (Ti) of cell after background subtraction at T0 and
T200 min. Picked cells which remained in prometaphase for the duration of the
200 min% degradation measured as (T0I – T200I)/ T0I.
Linescans were carried out using the BAR package in FIJI.
Mitochondrial lengths were analysed using MicroP55.
AURKA and AURKB biochemical assays. AURKA and AURKB biochemical
assays were performed as part of the ThermoFisher SelectScreen™ kinase profiling
service (see full experimental protocol in Supplementary Information). Com-
pounds were tested in AURKA or AURKB Z’-LYTE kinase assays using full-length
purified protein (3 nM for AURKA, 20 nM for AURKB) and ATP at Km (10 μM
for AURKA, 75 μM for AURKB). Across the three replicate assays, the assay Z’
averaged 0.87 for AURKA and 0.84 for AURKB.
Statistics and reproducibility. The number of biological repeats (two, three, or
four) for all experiments are indicated in figure legends. For live cell experiments
data are presented either as mean values ± SDs from biological repeats, or pooled
raw data as indicated in figure legends. For immunofluorescence analyses, two or
three cover-slips were prepared for each condition as technical repeats, with data
pooled from technical repeats but not biological repeats. Quantified data analyses
were plotted using GraphPad 6.01 (San Diego, CA, USA). Results were analyzed
with ANOVA, Student’s t-test or Mann–Whitney U-test (non-parametric) as
indicated in figure legends. Significant results are indicated as p < 0.05 (*), p ≤ 0.01
(**), p ≤ 0.001(***), p ≤ 0.0001 (****). Error bar values are stated as the
mean ± SDs.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper and its Supplementary Information files. 1H and 13C NMR and HRMS analyses
of the compounds described in this study are shown in the Supplementary Methods file.
Quantified data are assembled are available in Supplementary Data 1 file.
Received: 22 July 2020; Accepted: 29 April 2021;
References
1. Hanzl, A. & Winter, G. E. Targeted protein degradation: current and future
challenges. Curr. Opin. Chem. Biol. 56, 35–41 (2020).
2. Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule
PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
3. Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target
protein degradation. Science 348, 1376–1381 (2015).
4. Asteriti, I. A. et al. The Aurora-A inhibitor MLN8237 affects multiple mitotic
processes and induces dose-dependent mitotic abnormalities and aneuploidy.
Oncotarget 5, 6229–6242 (2014).
5. Manfredi, M. G. et al. Characterization of alisertib (MLN8237), an
investigational small-molecule inhibitor of aurora A kinase using novel in vivo
pharmacodynamic assays. Clin. Cancer Res. 17, 7614–7624 (2011).
6. de Groot, C. O. et al. A cell biologist’s field guide to aurora kinase inhibitors.
Front. Oncol. 5, 285 (2015).
7. Barr, A. R. & Gergely, F. Aurora-A: the maker and breaker of spindle poles. J.
Cell Sci. 120, 2987–2996 (2007).
8. Prosser, S. L. & Pelletier, L. Mitotic spindle assembly in animal cells: a fine
balancing act. Nat. Rev. Mol. Cell Biol. 18, 187–201 (2017).
9. Kufer, T. A. et al. Human TPX2 is required for targeting Aurora-A kinase to
the spindle. J. Cell Biol. 158, 617–623 (2002).
10. Joukov, V., De Nicolo, A., Rodriguez, A., Walter, J. C. & Livingston, D. M.
Centrosomal protein of 192 kDa (Cep192) promotes centrosome-driven
spindle assembly by engaging in organelle-specific Aurora A activation. Proc.
Natl Acad. Sci. USA 107, 21022–21027 (2010).
11. Bird, A. W. & Hyman, A. A. Building a spindle of the correct length in human
cells requires the interaction between TPX2 and Aurora A. J. Cell Biol. 182,
289–300 (2008).
12. Nikonova, A. S., Astsaturov, I., Serebriiskii, I. G., Dunbrack, R. L. & Golemis,
E. A. Aurora A kinase (AURKA) in normal and pathological cell division. Cell.
Mol. Life Sci. 70, 661–687 (2013).
13. Burgess, S. G. et al. Mitotic spindle association of TACC3 requires Aurora‐A‐
dependent stabilization of a cryptic α‐helix. EMBO J. 37, e97902 (2018).
14. Levinson, N. M. The multifaceted allosteric regulation of Aurora kinase A.
Biochem. J. 475, 2025–2042 (2018).
15. Dodson, C. A. & Bayliss, R. Activation of Aurora-A kinase by protein partner
binding and phosphorylation are independent and synergistic. J. Biol. Chem.
287, 1150–1157 (2012).
16. Zorba, A. et al. Molecular mechanism of Aurora A kinase
autophosphorylation and its allosteric activation by TPX2. eLife 3, e02667
(2014).
17. Booth, D. G., Hood, F. E., Prior, I. A. & Royle, S. J. A TACC3/ch-TOG/
clathrin complex stabilises kinetochore fibres by inter-microtubule bridging:
TACC3/ch-TOG/clathrin inter-microtubule bridges. EMBO J. 30, 906–919
(2011).
18. Floyd, S., Pines, J. & Lindon, C. APC/CCdh1 targets Aurora kinase to control
reorganization of the mitotic spindle at anaphase. Curr. Biol. 18, 1649–1658
(2008).
19. Honda, K. et al. Degradation of human Aurora2 protein kinase by the
anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 19,
2812–2819 (2000).
20. Plotnikova, O. V. et al. Calmodulin activation of Aurora-A kinase (AURKA) is
required during ciliary disassembly and in mitosis. MBoC 23, 2658–2670
(2012).
21. Büchel, G. et al. Association with Aurora-A controls N-MYC-dependent
promoter escape and pause release of RNA polymerase II during the cell cycle.
Cell Rep. 21, 3483–3497 (2017).
22. Byrum, A. K. et al. Mitotic regulators TPX2 and Aurora A protect DNA forks
during replication stress by counteracting 53BP1 function. J. Cell Biol. 218,
422–432 (2019).
23. Bertolin, G. et al. Aurora kinase A localises to mitochondria to control
organelle dynamics and energy production. Elife 7, e38111 (2018).
24. Abdelbaki, A. et al. AURKA destruction is decoupled from its activity at
mitotic exit but essential to suppress interphase activity. J. Cell Sci. 133,
jcs.243071 (2020).
25. Grant, R. et al. Constitutive regulation of mitochondrial morphology by
Aurora A kinase depends on a predicted cryptic targeting sequence at the N-
terminus. Open Biol 8, 170272 (2018).
26. Sackton, K. L. et al. Synergistic blockade of mitotic exit by two chemical
inhibitors of the APC/C. Nature 514, 646–649 (2014).
27. Courtheoux, T. et al. Aurora A kinase activity is required to maintain an active
spindle assembly checkpoint during prometaphase. J. Cell Sci. 131, jcs191353
(2018).
28. Wysong, D. R., Chakravarty, A., Hoar, K. & Ecsedy, J. A. The inhibition of
Aurora A abrogates the mitotic delay induced by microtubule perturbing
agents. Cell Cycle 8, 876–888 (2009).
29. Yu, F. et al. Aurora-A promotes the establishment of spindle assembly
checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase.
Cell Discov. 3, 16049 (2017).
30. Brito, D. A. & Rieder, C. L. Mitotic checkpoint slippage in humans occurs via
cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16,
1194–1200 (2006).
31. Collin, P., Nashchekina, O., Walker, R. & Pines, J. The spindle assembly
checkpoint works like a rheostat rather than a toggle switch. Nat. Cell Biol. 15,
1378–1385 (2013).
32. Littlepage, L. E. & Ruderman, J. V. Identification of a new APC/C recognition
domain, the A box, which is required for the Cdh1-dependent destruction of
the kinase Aurora-A during mitotic exit. Genes Dev. 16, 2274–2285 (2002).
33. Crane, R. Requirements for the destruction of human Aurora-A. J. Cell Sci.
117, 5975–5983 (2004).
34. Lindon, C., Grant, R. & Min, M. Ubiquitin-mediated degradation of aurora
kinases. Front. Oncol. 5, 307 (2015).
35. Salami, J. et al. Androgen receptor degradation by the proteolysis-targeting
chimera ARCC-4 outperforms enzalutamide in cellular models of prostate
cancer drug resistance. Commun. Biol. 1, 100 (2018).
36. Smith, B. E. et al. Differential PROTAC substrate specificity dictated by
orientation of recruited E3 ligase. Nat. Commun. 10, 131 (2019).
37. Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation
with a promiscuous warhead. Cell Chem. Biol. 25, 78–87 (2018).
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02158-2
14 COMMUNICATIONS BIOLOGY |           (2021) 4:640 | https://doi.org/10.1038/s42003-021-02158-2 | www.nature.com/commsbio
38. Joukov, V., Walter, J. C. & De Nicolo, A. The Cep192-organized Aurora A-
Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly.
Mol. Cell 55, 578–591 (2014).
39. Gallini, S. et al. NuMA phosphorylation by Aurora-A orchestrates spindle
orientation. Curr. Biol. 26, 458–469 (2016).
40. Lake, E. W. et al. Quantitative conformational profiling of kinase inhibitors
reveals origins of selectivity for Aurora kinase activation states. Proc. Natl
Acad. Sci. USA 115, E11894–E11903 (2018).
41. Bibby, R. A. et al. A cancer-associated Aurora A mutant is mislocalized and
misregulated due to loss of interaction with TPX2. J. Biol. Chem. 284,
33177–33184 (2009).
42. Giet, R. & Prigent, C. The non-catalytic domain of the Xenopus laevis auroraA
kinase localises the protein to the centrosome. J. Cell Sci. 114, 2095–2104
(2001).
43. Hirota, T. et al. Aurora-A and an interacting activator, the LIM protein Ajuba,
are required for mitotic commitment in human cells. Cell 114, 585–598 (2003).
44. Plotnikova, O. V., Pugacheva, E. N., Dunbrack, R. L. & Golemis, E. A. Rapid
calcium-dependent activation of Aurora-A kinase. Nat. Commun. 1, 64
(2010).
45. Bai, M. et al. Two newly identified sites in the N-terminal regulatory domain
of Aurora-A are essential for auto-inhibition. Biotechnol. Lett. 36, 1595–1604
(2014).
46. Chamberlain, P. P. & Hamann, L. G. Development of targeted protein
degradation therapeutics. Nat. Chem. Biol. 15, 937–944 (2019).
47. Lu, Y., Lee, B., King, R. W., Finley, D. & Kirschner, M. W. Substrate
degradation by the proteasome: a single-molecule kinetic analysis. Science 348,
1250834 (2015).
48. Kim, K. et al. Disordered region of cereblon is required for efficient
degradation by proteolysis-targeting chimera. Sci. Rep. 9, 19654 (2019).
49. Bayliss, R., Sardon, T., Vernos, I. & Conti, E. Structural basis of Aurora-A
activation by TPX2 at the mitotic spindle. Mol. Cell 12, 851–862 (2003).
50. Ruff, E. F. et al. A dynamic mechanism for allosteric activation of Aurora
kinase A by activation loop phosphorylation. eLife 7, e32766 (2018).
51. Floyd, S. et al. Spatiotemporal organization of Aurora-B by APC/CCdh1 after
mitosis coordinates cell spreading through FHOD1. J. Cell. Sci. 126,
2845–2856 (2013).
52. Zhu, F. et al. The mammalian SPD-2 ortholog Cep192 regulates centrosome
biogenesis. Curr. Biol. 18, 136–141 (2008).
53. Edelstein, A. D. et al. Advanced methods of microscope control using
μManager software. J. Biol. Methods 1, 10 (2014).
54. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis.
Nat. Methods 9, 676–682 (2012).
55. Peng, J.-Y. et al. Automatic morphological subtyping reveals new roles of
caspases in mitochondrial dynamics. PLoS Comput. Biol. 7, e1002212 (2011).
Acknowledgements
We thank Fanni Gergely and Laurent Pelletier for antibodies, Ian Storer, Zhongqian Sun
and Zhengxu Li for Cpd A and D resynthesis and for design and synthesis of Cpd DX.
Andreas Hock made valuable comments on the manuscript. R.W. was supported by
BBSRC-DTP, C.A. by a AstraZeneca-funded studentship and A.A. by a Yousef Jameel
Scholarship from the Cambridge International Trust. Work in C.L.’s lab is funded by
BBSRC (BB/R004137/1).
Author contributions
Study conceived and designed by C.L. and K.R. T.R. synthesized compounds used.
Experimental work was carried out and analysed by R.W., C.A., A.A., A.F. Manuscript
written by C.L., R.W., C.A., and revised by K.R., I.M., R.W., and C.A.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s42003-021-02158-2.
Correspondence and requests for materials should be addressed to C.L.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02158-2 ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:640 | https://doi.org/10.1038/s42003-021-02158-2 | www.nature.com/commsbio 15
